{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 42,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/13",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.77,
        "x": 0.118,
        "y": 0.819
      },
      "kind": "callout",
      "text": "APX3330 is the ONLY candidate with validated retinal pathways of angiogenesis and inflammation.\nHuman exposure >10,000 subject days of systemic exposure at 600mg/day dose and a favorable safety and tolerability profile.",
      "attrs": {},
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "062f473d-f681-4c0e-85ef-b7a3b5c1b3fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.17,
        "x": 0.73,
        "y": 0.72
      },
      "kind": "list",
      "text": "Completed Ongoing Discontinued",
      "attrs": {},
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f8df3e9-2f7c-4b74-9c99-68f095dd5cdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.357,
        "x": 0.357,
        "y": 0.72
      },
      "kind": "source-note",
      "text": "Note: Two Tyrosine Kinase and a Plasma Kallikrein Inhibitors failed as orals in Phase 2 due to dose limiting adverse events (e.g., liver and cardiovascular)",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aba9f999-d127-4da4-9fbd-d22726d87053",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.51,
        "w": 0.906,
        "x": 0.047,
        "y": 0.17
      },
      "kind": "table",
      "text": "Company Drug Target/MOA Indication Route of Administration Phase 1 Phase 2 Phase 3 Primary Endpoint/ Secondary Endpoints\nOcuphire APX3330 Ref-1 inhibitor (Anti-angiogenesis & Anti-inflammatory) DR Oral ✓ 2022 2020: 2-step DRSS @wk24\nRoche RG7774 CB2 receptor (cannabinoid) DR Oral ✓ X 2023 2020: 2-step DRSS @wk36\nBAYER BAY1101042 Guanylate Cyclase activator DR Oral ✓ 2021: 2-step DRSS @wk24\nValo OPL-0401 ROCK 1/2 inhibitor DR Oral ✓ 2021: 2-step DRSS @wk24\nVantage VX-01 AOC-3 inhibitor DR Oral ✓ 2022: Not Disclosed\nOCUTERRA OTT166 Integrin inhibitor DR Eyedrop ✓ 2022: 2-step DRSS @wk24",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f21669e2-f443-4722-91ec-b0aa8922e4ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.76,
        "x": 0.047,
        "y": 0.08
      },
      "kind": "title",
      "text": "Ocuphire's APX3330 is the Most Advanced Oral Drug Candidate",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "271b9a63-0eba-4434-ba9f-2a7bab1cf963",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.909,
        "x": 0.047,
        "y": 0.047
      },
      "kind": "title",
      "text": "Landscape of Investigational Non-Invasive Therapies for Diabetic Retinopathy",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b20e204f-dad2-4b57-8ce3-4b60701e9d00",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 11,
      "beatId": "658ab0ae-6284-4b3b-b67a-e6c8bfbdd666",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 11-16 present APX3330 as a solution for Diabetic Retinopathy",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}